



WE CLAIM:

1. A compound of Formula (I) or Formula (II), or pharmaceutically acceptable salt thereof:



wherein:

m is 1 and R²⁰ is selected from H, halo, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆haloalkoxy, deuterium, deuterated C₁-C₆alkyl, -CN, -(CR⁹₂)_nOR⁴, -C(O)R⁴, -(CR⁹₂)_nC(=O)OR⁴, R¹⁰, -(CR⁹₂)_nR¹⁰, -(CR⁹₂)_nO(R⁴), -(CR⁹₂)_nO(CR⁹₂)_nR⁷, -(CR⁹₂)_nC(=O)R⁴, -C(=O)N(R⁴)₂, -OR⁴ and -(CR⁹₂)_nCN;

or m is 4 and R²⁰ is deuterium;

R¹ is selected from C₁-C₆alkyl and halo;

each R¹¹ is independently selected from H, halo, and C₁-C₆alkyl;

L₁ is a bond, -NH- or -C(=O)NH-;

L₂ is -(CR⁹₂)_n-, -CH(R⁶)-, -(CR⁹₂)_nO-, -NH-, -(CR⁹₂)_nC(=O)-, -C(=O)O(CR⁹₂)_n-, -(CR⁹₂)_nOC(=O)NR⁴-, -(CR⁹₂)_nNR⁴C(=O)(CR⁹₂)_n-, -(CR⁹₂)_nNR⁴C(=O)- or -(CR⁹₂)_nNR⁴C(=O)O-;

R² is R³ or L₂R³;

R³ is selected from an unsubstituted C₃-C₈cycloalkyl, a cyclobutanone, a cyclopentanone and a substituted C₃-C₈cycloalkyl,

wherein the substituted C₃-C₈cycloalkyl of R² is substituted with 1-4

substituents independently selected from C₁-C₆alkyl, halo, C₁-C₆haloalkyl, -OR⁴, -CN, -C(=O)OR⁴, -C(=O)R⁴, -C(=O)R⁷, -C(=O)OR⁵, -(CR⁹₂)_nOR⁴, -O(CR⁹₂)_nOR⁴, -C(=O)O(CR⁹₂)_nOR⁴, -N(R⁴)₂, =N-OR⁴, =N-O-(CR⁹₂)_nR⁵, -C(=O)NR⁴₂, -NR⁴C(=O)OR⁴, -NR⁴C(=O)(CR⁹₂)_nOR⁴, -NR⁴(CR⁹₂)_nOR⁴, -NR⁴S(=O)₂R⁴, -N(C(=O)OR⁴)₂, =CH₂, =CH(CR⁹₂)_nOR⁴, R⁸, -(CR⁹₂)_nR⁸, deuterated C₁-C₆alkoxy, -S(=O)₂R⁴, -S(=O)₂R⁷, -S(=O)₂R⁸, -S(=O)₂N(R⁴)₂, -S(=O)₂NHC(=O)OR⁴, -S(=O)₂(CR⁹₂)_nC(=O)OR⁴, -S(=O)₂(CR⁹₂)_nOR⁴, a spiro attached dioxolane, a spiro attached dioxolane which is substituted with C₁-C₆alkyl, a spiro attached

5

dioxane, a spiro attached tetrahydrofuranly, a spiro attached oxetane, a spiro attached cyclobutanone, a spiro attached cyclobutanol, a C₁ alkyl bridge, an unsubstituted 5-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O and S, a 5-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O and S substituted with 1-3 substituents independently selected from C₁-C₆alkyl, halo, C₁-C₆haloalkyl, C₁-C₆haloalkoxy, -OR⁴ and R⁸;

10

each R⁴ is independently selected from H and C₁-C₆alkyl;

R⁵ is an unsubstituted C₃-C₈cycloalkyl, an unsubstituted 5-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N or O or a C₃-C₈cycloalkyl substituted with 1-3 substituents independently selected from C₁-C₆alkyl;

15

each R⁶ is independently selected from -NHC(O)OR⁴, -OR⁴ and -(CR⁹)_nOR⁴;

each R⁷ is independently selected from C₁-C₆haloalkyl;

20

R⁸ is selected from an unsubstituted phenyl, unsubstituted 5-6 membered heteroaryl with 1-3 heteroatoms independently selected from N, O or S, an unsubstituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, an unsubstituted 4-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O or S, an unsubstituted C₃-C₈cycloalkyl, a substituted 5-6 membered heteroaryl with 1-3 heteroatoms independently selected from N, O or S, a substituted phenyl, a substituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, a substituted 4-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O or S, a substituted C₃-C₈cycloalkyl, a oxazolidin-2-one, pyrrolidinone and a pyrrolidin-2-one,

25

wherein the substituted phenyl, the substituted 5-6 membered heteroaryl with 1-3 heteroatoms independently selected from N, O or S, the substituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, substituted C₃-C₈cycloalkyl and substituted 4-6 membered heterocycloalkyl of R⁸ are substituted with 1-3 substituents independently selected from C₁-C₆alkyl, -(C(R⁹))₂_nOR⁴, -(C(R⁹))₂_nR⁵, -(C(R⁹))₂_nC(O)OR⁴, -C(O)OR⁴ and -S(O)₂R⁴;

30

each R⁹ is independently selected from H and C₁-C₆alkyl;

35

R¹⁰ is selected from an unsubstituted phenyl, unsubstituted 5-6 membered heteroaryl with 1-2 heteroatoms independently selected from N, O or S, an unsubstituted 5 membered heteroaryl with 1-4 heteroatoms selected


from N, an unsubstituted 4-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O or S, an unsubstituted C₃-C₆cycloalkyl, a substituted 5-6 membered heteroaryl with 1-2 heteroatoms independently selected from N, O or S, a substituted phenyl, a substituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, a substituted 4-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O or S, a substituted C₃-C₆cycloalkyl, a oxazolidin-2-one, pyrrolidinone and a pyrrolidin-2-one

wherein the substituted phenyl, the substituted 5-6 membered heteroaryl with 1-2 heteroatoms independently selected from N, O or S, the substituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, substituted C₃-C₆cycloalkyl and substituted 4-6 membered heterocycloalkyl of R⁸ are substituted with 1-3 substituents independently selected from C₁-C₆alkyl, -(C(R⁹)₂)_nOR⁴, -(C(R⁹)₂)_nR⁵, -(C(R⁹)₂)_nC(O)OR⁴ and -S(O)_t-R⁴;


t is 1, 2 or 3, and

each n is independently selected from 1, 2, 3 and 4.


2. The compound of claim 1, wherein the compound is a compound of Formula (Ia), Formula (IIa), Formula (Ib) or Formula (IIb):




Formula (Ia)



Formula (IIa)



Formula (Ib)



Formula (IIb)

wherein:

m is 1 and R²⁰ is selected from H, halo, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆haloalkoxy, deuterium, deuterated C₁-C₆alkyl, -CN, -(C(R⁹)₂)_nOR⁴, -

179

$C(O)R^4$, $-(CR^9)_n C(=O)OR^4$, R^{10} , $-(CR^9)_n R^{10}$, $-((CR^9)_n O)R^4$, $-(CR^9)_n O(CR^9)_n R^7$, $-(CR^9)_n C(=O)R^4$, $-C(=O)N(R^4)_2$, $-OR^4$ and $-(CR^9)_n CN$;

or m is 4 and R^{20} is deuterium;

R^1 is selected from C_1 - C_6 alkyl and halo;

5 each R^{11} is independently selected from H, halo, and C_1 - C_6 alkyl;

L_2 is $-(CR^9)_n$, $-CHR^6$, $-(CR^9)_n O$, $-NH$, $-(CR^9)_n C(=O)$, $-C(=O)O(CR^9)_n$, $-(CR^9)_n OC(=O)NR^4$, $-(CR^9)_n NR^4 C(=O)(CR^9)_n$, $-(CR^9)_n NR^4 C(=O)-$ or $-(CR^9)_n NR^4 C(=O)O-$;

R^2 is R^3 or $L_2 R^3$;

10 R^3 is selected from an unsubstituted C_3 - C_8 cycloalkyl, a cyclobutanone, a cyclopentanone and a substituted C_3 - C_8 cycloalkyl,

wherein the substituted C_3 - C_8 cycloalkyl of R^2 is substituted with 1-4

15 substituents independently selected from C_1 - C_6 alkyl, halo, C_1 - C_6 haloalkyl, $-OR^4$, $-CN$, $-C(=O)OR^4$, $-C(=O)R^4$, $-C(=O)R^7$, $-C(=O)OR^5$, $-(CR^9)_n OR^4$, $-O(CR^9)_n OR^4$, $-C(=O)O(CR^9)_n OR^4$, $-N(R^4)_2$, $=N-OR^4$, $=N-O$, $-(CR^9)_n R^5$, $-C(=O)NR^4$, $-NR^4 C(=O)OR^4$, $-NR^4 C(=O)(CR^9)_n OR^4$, $-NR^4 (CR^9)_n OR^4$, $-NR^4 S(=O)_2 R^4$, $-N(C(=O)OR^4)_2$, $=CH_2$, $=CH(CR^9)_n OR^4$, R^8 , $-(CR^9)_n R^8$, deuterated C_1 - C_6 alkoxy, $-S(=O)_2 R^4$, $-S(=O)_2 R^7$, $-S(=O)_2 R^8$, $-S(=O)_2 N(R^4)_2$, $-S(=O)_2 NHC(=O)OR^4$, $-S(=O)_2 (CR^9)_n C(=O)OR^4$, $-S(=O)_2 (CR^9)_n OR^4$, a spiro attached dioxolane, a spiro attached dioxolane which is substituted with C_1 - C_6 alkyl, a spiro attached dioxane, a spiro attached tetrahydrofuran, a spiro attached oxetane, a spiro attached cyclobutanone, a spiro attached cyclobutanol, a C_1 alkyl bridge, an unsubstituted 5-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O and S, a 5-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O and S substituted with 1-3 substituents independently selected from C_1 - C_6 alkyl, halo, C_1 - C_6 haloalkyl, C_1 - C_6 haloalkoxy, $-OR^4$ and R^8 ;

20 $-S(=O)_2 NHC(=O)OR^4$, $-S(=O)_2 (CR^9)_n C(=O)OR^4$, $-S(=O)_2 (CR^9)_n OR^4$, a spiro attached dioxolane, a spiro attached dioxolane which is substituted with C_1 - C_6 alkyl, a spiro attached dioxane, a spiro attached tetrahydrofuran, a spiro attached oxetane, a spiro attached cyclobutanone, a spiro attached cyclobutanol, a C_1 alkyl bridge, an unsubstituted 5-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O and S, a 5-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O and S substituted with 1-3 substituents independently selected from C_1 - C_6 alkyl, halo, C_1 - C_6 haloalkyl, C_1 - C_6 haloalkoxy, $-OR^4$ and R^8 ;

30 each R^4 is independently selected from H and C_1 - C_6 alkyl;

R^5 is an unsubstituted C_3 - C_8 cycloalkyl, an unsubstituted 5-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N or O or a C_3 - C_8 cycloalkyl substituted with 1-3 substituents independently selected from C_1 - C_6 alkyl;

35 each R^6 is independently selected from $-NHC(=O)OR^4$, $-OR^4$ and $-(CR^9)_n OR^4$;

each R^7 is independently selected from C_1 - C_6 haloalkyl;

5 R^8 is selected from an unsubstituted phenyl, unsubstituted 5-6 membered heteroaryl with 1-3 heteroatoms independently selected from N, O or S, an unsubstituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, an unsubstituted 4-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O or S, an unsubstituted C_3 - C_8 cycloalkyl, a substituted 5-6 membered heteroaryl with 1-3 heteroatoms independently selected from N, O or S, a substituted phenyl, a substituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, a substituted 4-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O or S, a substituted C_3 - C_8 cycloalkyl, a oxazolidin-2-one, pyrrolidinone and a pyrrolidin-2-one, wherein the substituted phenyl, the substituted 5-6 membered heteroaryl with 1-3 heteroatoms independently selected from N, O or S, the substituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, substituted C_3 - C_8 cycloalkyl and substituted 4-6 membered heterocycloalkyl of R^8 are substituted with 1-3 substituents independently selected from C_1 - C_6 alkyl, $-(C(R^9)_2)_nOR^4$, $-(C(R^9)_2)_nR^5$, $-(C(R^9)_2)_nC(O)OR^4$, $-C(O)OR^4$ and $-S(O)_2R^4$;

10 each R^9 is independently selected from H and C_1 - C_6 alkyl;

15 R^{10} is selected from an unsubstituted phenyl, unsubstituted 5-6 membered heteroaryl with 1-2 heteroatoms independently selected from N, O or S, an unsubstituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, an unsubstituted 4-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O or S, an unsubstituted C_3 - C_8 cycloalkyl, a substituted 5-6 membered heteroaryl with 1-2 heteroatoms independently selected from N, O or S, a substituted phenyl, a substituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, a substituted 4-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O or S, a substituted C_3 - C_8 cycloalkyl, a oxazolidin-2-one, pyrrolidinone and a pyrrolidin-2-one, wherein the substituted phenyl, the substituted 5-6 membered heteroaryl with 1-2 heteroatoms independently selected from N, O or S, the substituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, substituted C_3 - C_8 cycloalkyl and substituted 4-6 membered heterocycloalkyl of R^{10} are substituted with 1-3 substituents independently selected from C_1 - C_6 alkyl, $-(C(R^9)_2)_nOR^4$, $-(C(R^9)_2)_nR^5$, $-(C(R^9)_2)_nC(O)OR^4$ and $-S(O)_2R^4$;

20

25

30

35

t is 1, 2 or 3, and

each n is independently selected from 1, 2, 3 and 4.

3. The compound of claim 1 or claim 2, wherein R^1 is selected from $-CH_3$ and F.
4. The compound of any one of claims 1 to 3, wherein R^1 is $-CH_3$.
5. The compound of any one of claims 1 to 4, wherein each R^{11} is independently selected from H, F and $-CH_3$.
6. The compound of any one of claims 1 to 5, wherein each R^{11} is H.
7. The compound of any one of claims 1 to 6, wherein R^3 is selected from an unsubstituted C_3 - C_8 cycloalkyl, a cyclobutanone, a cyclopentanone and a substituted C_3 - C_8 cycloalkyl,
wherein the substituted C_3 - C_8 cycloalkyl of R^3 is substituted with 1-4 substituents independently selected from C_1 - C_6 alkyl, halo, C_1 - C_6 haloalkyl, $-OR^4$, $-(CR^9_2)_nOR^4$, $-O(CR^9_2)_nOR^4$, $-N(R^4)_2$, $=NOR^4$, $=N-O-(CR^9_2)_nR^5$, $-NR^4C(=O)OR^4$, $-NR^4C(=O)(CR^9_2)_nOR^4$, $-NR^4(CR^9_2)_nOR^4$, $-NR^4S(=O)_2R^4$, $-N(C(=O)OR^4)_2$, $=CH_2$, $=CH(CR^9_2)_nOR^4$, R^8 , deuterated C_1 - C_6 alkoxy, a spiro attached dioxolane, a spiro attached dioxolane which is substituted with C_1 - C_6 alkyl, a spiro attached dioxane, a spiro attached tetrahydrofuranly, a spiro attached cyclobutanone, a spiro attached cyclobutanol, an unsubstituted 5-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N and O and a 5-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N and O substituted with 1-3 substituents independently selected from C_1 - C_6 alkyl.
8. The compound of any one of claims 1 to 7, wherein each R^4 is independently selected from H, methyl, ethyl, propyl, butyl, i-propyl and t-butyl.
9. The compound of any one of claims 1 to 8, wherein R^5 is independently selected from cyclopropyl or morpholinyl.
10. The compound of any one of claims 1 to 9, wherein each R^7 is independently selected from CH_2F , $-CHF_2$, $-CH_2CHF_2$, $-CH_2CF_3$ and $-CF_3$.
11. The compound of any one of claims 1 to 10, wherein each R^9 is independently selected from H, methyl and ethyl.
12. The compound of any one of claims 1 to 11, wherein R^8 is selected from an unsubstituted C_3 - C_8 cycloalkyl and an unsubstituted 5 membered heteroaryl with 1-4 heteroatoms selected from N.
13. The compound of any one of claims 1 to 12, wherein

R^3 is selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, each of which is unsubstituted or each of which is substituted with 1-4 substituents independently selected from -F, -CH₃, -CH₂CH₃, -CF₃, -OH, -OCH₃, -CH₂OCH₃, -NH₂, -N(CH₃)₂, -OCH₂CH₂OCH₃, =N-OCH₃, =N-OCH₂CH₃, =N-OCH(CH₃)₂, =N-OH, =N-O-CH₂R⁵, =N-O-CH₂CH₂R⁵, -NHC(=O)OC(CH₃)₃, -NHC(=O)OCH₃, -NHC(=O)CH₂OCH₃, -NHCH₂CH₂OCH₃, -NHCH₂CH₂OH, -NHS(=O)₂CH₃, -N(C(=O)OCH₃)₂, =CH₂, =CHCH₂CH₂OH, -OCD₃, cyclopropyl, triazolyl, pyrazolyl, a spiro attached dioxolane, a spiro attached dioxolane which is substituted with a -CH₃, a spiro attached dioxane, a spiro attached tetrahydrofuran, a spiro attached cyclobutanone, a spiro attached cyclobutanol, piperidinyl and piperazinyl substituted with a -CH₃,

or R^3 is a cyclobutanone or a cyclopentanone.

14. The compound of any one of claims 1 to 13, wherein:

15 R^3 is cyclopropyl substituted with 1 or 2 F,

or

R^3 is cyclobutyl substituted with 2 F.

15. The compound of any one of claims 1 to 14, wherein m is 1 and R^{20} is selected from H, halo, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆haloalkoxy, deuterated C₁-C₆alkyl, -CN, -(CR⁹)_nOR⁴, -(CR⁹)_nC(=O)OR⁴, R¹⁰, -(CR⁹)_nR¹⁰, -((CR⁹)_nO)_tR⁴, -(CR⁹)_nO(CR⁹)_nR⁷, -(CR⁹)_nC(=O)R⁴, and -C(=O)N(R⁴)₂.

16. The compound of any one of claims 1 to 15, wherein m is 1 and R^{20} is selected from H, -F, -CH₃, -CF₃, -CD₃, -CN, -OCHF₂, -C(CH₃)OH, -CH₂CH₂C(=O)OC(CH₃)₃, -CH₂OCH₂CH₂OH, -CH₂OCH₂CF₃, -C(=O)NH₂, -CH₂CH₂C(CH₃)₂OH, -CH₂OCH₂CH₂OCH₃, -CH₂OCH₂CH₂F, -CH₂CH₂C(=O)CH₃, -CH₂OH and -CH₂OCH₃.

17. The compound of any one of claims 1 to 16, wherein m is 1 and R^{20} is -CH₃.

18. The compound of any one of claims 1 to 16, wherein m is 1 and R^{20} is H.

19. The compound of any one of claims 1 to 18, wherein:

30 R^{10} is selected from morpholinyl, piperidinyl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazinyl, piperazin-1-yl, pyrazolyl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, triazolyl, 1H-1,2,3-triazol-4-yl, 4H-1,2,4-triazol-3-yl, 1H-1,2,4-triazol-5-yl, thiazolyl, thiazol-4-yl, thiazol-5-yl, imidazolyl, imidazol-1-yl, imidazol-2-yl, each of which is unsubstituted or each of which is substituted with 1-3 substituents independently selected

from C₁-C₆alkyl, -(CR⁹)_nOR⁴, -(C(R⁹)₂)_nC(O)OR⁴, -(C(R⁹)₂)_nR⁵ and -S(=O)₂R⁴,

or R¹⁰ is selected from a oxazolidin-2-one and a pyrrolidin-2-one.

20. The compound of any one of claims 1 to 19, wherein:

5 R¹⁰ is selected from morpholinyl, piperidinyl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazinyl, piperazin-1-yl, pyrazolyl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, triazolyl, 1H-1,2,3-triazol-4-yl, 4H-1,2,4-triazol-3-yl, 1H-1,2,4-triazol-5-yl, thiazolyl, thiazol-4-yl, thiazol-5-yl, imidazolyl, imidazol-1-yl, imidazol-2-yl, each of which is unsubstituted or
10 each of which is substituted with 1-3 substituents independently selected from -CH₃, -CH₂CH₂OH, -CH₂C(O)OH, -CH₂CH₂OH, -CH₂C(CH₃)₂OH, -S(O)₂CH₃ and -CH₂CH₂-R₅.

21. The compound of any one of claims 1 to 14, wherein m is 4 and R²⁰ is deuterium.

22. The compound of claim 1 selected from:

15 N-{5-[3-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-5-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
N-{2-methyl-5-[5-(3-oxocyclopentyl)-1,2,4-oxadiazol-3-yl]phenyl}imidazo[1,2-a]pyridine-3-carboxamide;
N-{5-[5-(3-hydroxy-3-methylcyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
20 N-{5-[5-[3-(hydroxyimino)cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
N-{5-[5-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
25 N-{5-[5-(3-hydroxy-3-methylcyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
N-{5-[5-[3-(methoxyimino)cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
N-{5-[5-(5,8-dioxaspiro[3.4]octan-2-yl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
30 N-(2-methyl-5-[5-[(6R)-6-methyl-5,8-dioxaspiro[3.4]octan-2-yl]-1,2,4-oxadiazol-3-yl]phenyl)imidazo[1,2-a]pyridine-3-carboxamide;
N-[5-(5-[5,9-dioxaspiro[3.5]nonan-2-yl]-1,2,4-oxadiazol-3-yl)-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
35 N-(2-methyl-5-[5-(3-oxocyclobutyl)-1,2,4-oxadiazol-3-yl]phenyl)imidazo[1,2-a]pyridine-3-carboxamide;

- N-(2-methyl-5-{5-[(6S)-6-methyl-5,8-dioxaspiro[3.4]octan-2-yl]-1,2,4-oxadiazol-3-yl}phenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 5 N-(5-{5-[3-(ethoxyimino)cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-[5-{5-[3-[(cyclopropylmethoxy)imino]cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-[2-methyl-5-{5-[3-[(propan-2-yloxy)imino]cyclobutyl]-1,2,4-oxadiazol-3-yl}phenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- 10 N-{5-[5-(3-aminocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-(5-{5-[3-(2-methoxyethoxy)cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 15 N-[5-[5-(3-methoxycyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-(5-{5-[1-(methoxymethyl)cyclopropyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- tert-butyl N-{1-[3-(3-{imidazo[1,2-a]pyridine-3-amido}-4-methylphenyl)-1,2,4-oxadiazol-5-yl]cyclopropyl}carbamate;
- 20 N-[5-[5-(1-methanesulfonamidocyclopropyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- methyl N-{1-[3-(3-{imidazo[1,2-a]pyridine-3-amido}-4-methylphenyl)-1,2,4-oxadiazol-5-yl]cyclopropyl}-N-(methoxycarbonyl)carbamate;
- 25 methyl N-{1-[3-(3-{imidazo[1,2-a]pyridine-3-amido}-4-methylphenyl)-1,2,4-oxadiazol-5-yl]cyclopropyl}carbamate;
- N-(5-{5-[3-hydroxy-3-(trifluoromethyl)cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 1-methylcyclopropyl N-{[3-(3-{imidazo[1,2-a]pyridine-3-amido}-4-methylphenyl)-1,2,4-oxadiazol-5-yl]methyl}carbamate;
- 30 methyl N-{1-[3-(3-{imidazo[1,2-a]pyridine-3-amido}-4-methylphenyl)-1,2,4-oxadiazol-5-yl]cyclobutyl}carbamate;
- N-[5-[5-(1-methanesulfonamidocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- 35 N-(5-{5-[1-(dimethylamino)cyclopropyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;

185

- N-{2-methyl-5-[5-(3-methylidenecyclobutyl)-1,2,4-oxadiazol-3-yl]phenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3-cyclopropyl-3-hydroxycyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 5 N-{5-[5-[3-(3-hydroxypropylidene)cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-[2-methyl-5-(5-[5-oxaspiro[3.4]octan-2-yl]-1,2,4-oxadiazol-3-yl)phenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-[5-(5-[(3,3-difluorocyclobutyl)amino]methyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 10 N-(2-methyl-5-[5-[(2,2,3,3-tetrafluorocyclobutoxy)methyl]-1,2,4-oxadiazol-3-yl]phenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3-fluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 15 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(hydroxymethyl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[(2-hydroxyethoxy)methyl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(methoxymethyl)imidazo[1,2-a]pyridine-3-carboxamide;
- 20 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide;
- 25 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(1-methyl-1H-pyrazol-3-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide;
- 30 N-(2-methyl-5-[5-[3-(1H-pyrazol-1-yl)cyclobutyl]-1,2,4-oxadiazol-3-yl]phenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(1,3-thiazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- 35 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-fluorophenyl}-6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide;

- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-fluorophenyl}-6-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-7-(1-methanesulfonylpiperidin-4-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- 5 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[1-(2-(morpholin-4-yl)ethyl)-1H-pyrazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-fluorophenyl}-6-[1-(2-(morpholin-4-yl)ethyl)-1H-pyrazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide;
- 10 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[(2,2,2-trifluoroethoxy)methyl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(3-oxobutyl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(3-hydroxy-3-methylbutyl)imidazo[1,2-a]pyridine-3-carboxamide;
- 15 N-{5-[5-[2-(1-hydroxycyclopropyl)ethyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[2-(morpholin-4-yl)ethyl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(cyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 20 N-{5-[5-(3,3-dimethylcyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-7-(morpholin-4-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- 25 6-cyano-N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-fluorophenyl}-6-(5-methyl-4H-1,2,4-triazol-3-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- 30 3-N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3,6-dicarboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[2-(4-methylpiperazin-1-yl)ethyl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(2,2-difluorocyclopropyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 35 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-7-(1H-1,2,3-triazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide;

- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-7-[1-(2-hydroxyethyl)-1H-1,2,3-triazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2,4-dimethylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 5 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-7-(2-oxo-1,3-oxazolidin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-7-methylimidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-methylimidazo[1,2-a]pyridine-3-carboxamide;
- 10 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-fluoroimidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-7-fluoroimidazo[1,2-a]pyridine-3-carboxamide;
- 15 7-cyano-N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-[5-(5-cyclopentyl-1,2,4-oxadiazol-3-yl)-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-[2-methyl-5-(5-{6-oxospiro[3.3]heptan-2-yl}-1,2,4-oxadiazol-3-yl)phenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- 20 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-7-(2-oxopyrrolidin-1-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[(2,2-difluoroethoxy)methyl]imidazo[1,2-a]pyridine-3-carboxamide;
- 25 N-{5-[5-(3-ethylcyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(5-methyl-4H-1,2,4-triazol-3-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-7-methylimidazo[1,2-a]pyridine-3-carboxamide;
- 30 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(morpholin-4-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(1H-imidazol-1-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- 35 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[(2-fluoroethoxy)methyl]imidazo[1,2-a]pyridine-3-carboxamide;

- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[3-(methoxymethyl)-1H-1,2,4-triazol-5-yl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(2,2-difluorocyclopropyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[(2,2,2-trifluoroethoxy)methyl]imidazo[1,2-a]pyridine-3-carboxamide;
- 5 N-{5-[5-(cyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[(2,2,2-trifluoroethoxy)methyl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-[(1R)-2,2-difluorocyclopropyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-[(1S)-2,2-difluorocyclopropyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 10 N-{5-[5-[3-hydroxy-3-(trifluoromethyl)cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-7-methylimidazo[1,2-a]pyridine-3-carboxamide;
- 6-fluoro-N-{5-[5-[3-hydroxy-3-(trifluoromethyl)cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 15 N-{5-[5-[(1R,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-5,6,7,8-tetradeuteroimidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[(3,3-difluorocyclobutyl)carbamoyl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 20 7-fluoro-N-{5-[5-[3-hydroxy-3-(trifluoromethyl)cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(4-methyl-1H-imidazol-1-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- 25 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-[3-methoxy-3-(trifluoromethyl)cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 6-fluoro-N-{5-[5-[1-(methoxymethyl)cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 30 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[1-(2-methoxyethyl)-5-methyl-1H-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-[6-hydroxyspiro[3.3]heptan-2-yl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 35 N-{5-[5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;

- 7-methyl-N-(2-methyl-5-{5-[(2,2,3,3-tetrafluorocyclobutoxy)methyl]-1,2,4-oxadiazol-3-yl}phenyl)imidazo[1,2-a]pyridine-3-carboxamide;
6-methyl-N-(2-methyl-5-{5-[(2,2,3,3-tetrafluorocyclobutoxy)methyl]-1,2,4-oxadiazol-3-yl}phenyl)imidazo[1,2-a]pyridine-3-carboxamide;
5 N-[5-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
N-[5-[5-(cyclopropylmethyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
N-(5-{5-[(1R,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine-3-carboxamide;
10 N-(5-{5-[(1S,2R)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine-3-carboxamide;
N-(5-{5-[(1R)-2,2-difluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-2,4-dimethylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
15 N-(5-{5-[(1S)-2,2-difluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-2,4-dimethylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
N-(5-{5-[(1R,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
N-[5-[5-(3-fluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-7-methylimidazo[1,2-a]pyridine-3-carboxamide;
20 N-[5-[5-(3-fluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-6-methylimidazo[1,2-a]pyridine-3-carboxamide;
N-(5-{5-[(1S,2R)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
25 methyl N-{3,3-difluoro-1-[3-(3-{imidazo[1,2-a]pyridine-3-amido}-4-methylphenyl)-1,2,4-oxadiazol-5-yl]cyclobutyl}carbamate;
methyl N-{3,3-difluoro-1-[3-(4-methyl-3-{7-methylimidazo[1,2-a]pyridine-3-amido}phenyl)-1,2,4-oxadiazol-5-yl]cyclobutyl}carbamate, and
N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-6-[(2-fluoroethoxy)methyl]imidazo[1,2-a]pyridine-3-carboxamide.
30
23. The compound of claim 1 selected from:
N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
N-(5-{5-[(1R)-2,2-difluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
35

N-(5-{5-[(1S)-2,2-difluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;

N-(5-{5-[(1S,2R)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide, and

5 N-(5-{5-[(1R,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide.

24. A pharmaceutical composition comprising a therapeutically effective amount a compound of any one of claims 1 to 23 and a pharmaceutically acceptable carrier.

10 25. A medicament for treating a disease mediated by a kinase in a patient in need thereof, wherein the medicaments comprises a therapeutically effective amount of a compound of any one of claims 1 to 23, the kinase is selected from c-kit, PDGFR α , and PDGFR β , and the disease is a mast-cell associated disease, a respiratory disease, an inflammatory disorder, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), an autoimmune disorder, a metabolic disease, a fibrosis disease, a dermatological disease, pulmonary arterial hypertension (PAH) or
15 primary pulmonary hypertension (PPH).

26. The medicament of claim 25, wherein the disease is asthma, allergic rhinitis, pulmonary arterial hypertension (PAH), pulmonary fibrosis, hepatic fibrosis, cardiac fibrosis, scleroderma, irritable bowel syndrome (IBS), inflammatory bowel disease
20 (IBD), urticaria, dermatosis, type I diabetes or type II diabetes.

27. Use of a compound of any one of claims 1 to 23 in the manufacture of a medicament for treating a disease or disorder in a patient where modulation of a kinase is implicated, wherein the kinase is selected from c-kit, PDGFR α and PDGFR β .


25 28. A method for treating a disease or disorder where modulation of a kinase is implicated, wherein the method comprises administering to a system or subject in need of such treatment an effective amount of a compound of any one of claims 1 to 23, wherein the kinase is selected from c-kit, PDGFR α and PDGFR β .

29. The method of claim 28, wherein the disease is a mast-cell associated disease, a
30 respiratory disease, an inflammatory disorder, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), an autoimmune disorder, a metabolic disease, a fibrosis disease, a dermatological disease, pulmonary arterial hypertension (PAH) or primary pulmonary hypertension (PPH).


30. The method of claim 29, wherein the disease is asthma, allergic rhinitis, pulmonary arterial hypertension (PAH), pulmonary fibrosis, hepatic fibrosis, cardiac fibrosis, scleroderma, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), urticaria, dermatosis, type I diabetes or type II diabetes.
- 5 31. A method for modulating kinase activity, comprising administering to a system or a subject in need thereof, a therapeutically effective amount of the compound of any one of claims 1 to 23 or pharmaceutically acceptable salts or pharmaceutical compositions thereof, wherein the kinase is c-kit, PDGFR α and PDGFR β .
- 10 32. A compound any one of claims 1 to 23 for use in treating a disease mediated by c-kit, PDGFR α , PDGFR β or combination thereof, wherein the disease is selected from a mast-cell associated disease, a respiratory disease, an inflammatory disorder, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), an autoimmune disorder, a metabolic disease, a fibrosis disease, a dermatological disease, pulmonary arterial hypertension (PAH) and primary pulmonary hypertension (PPH).
- 15 33. The compound of claim 32, wherein the disease is asthma, allergic rhinitis, pulmonary arterial hypertension (PAH), pulmonary fibrosis, hepatic fibrosis, cardiac fibrosis, scleroderma, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), urticaria, dermatosis, type I diabetes or type II diabetes.
- 20

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A compound of Formula (I) or Formula (II), or pharmaceutically acceptable salt thereof:



Formula (I)



Formula (II)

wherein:

m is 1 and R^{20} is selected from H, halo, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 haloalkoxy, deuterium, deuterated C_1 - C_6 alkyl, -CN, $-(CR^9_2)_nOR^4$, $-C(O)R^4$, $-(CR^9_2)_nC(=O)OR^4$, R^{10} , $-(CR^9_2)_nR^{10}$, $-(CR^9_2)_nO$, $-(CR^9_2)_nO(CR^9_2)_nR^7$, $-(CR^9_2)_nC(=O)R^4$, $-C(=O)N(R^4)_2$, $-OR^4$ and $-(CR^9_2)_nCN$;

or m is 4 and R^{20} is deuterium;

R^1 is selected from C_1 - C_6 alkyl and halo;

each R^{11} is independently selected from H, halo, and C_1 - C_6 alkyl;

L_1 is a bond, -NH- or $-C(=O)NH-$;

L_2 is $-(CR^9_2)_n-$, $-CHR^6-$, $-(CR^9_2)_nO-$, $-NH-$, $-(CR^9_2)_nC(=O)-$, $-C(=O)O(CR^9_2)_n-$, $-(CR^9_2)_nOC(=O)NR^4-$, $-(CR^9_2)_nNR^4C(=O)(CR^9_2)_n-$, $-(CR^9_2)_nNR^4C(=O)-$ or $-(CR^9_2)_nNR^4C(=O)O-$;

R^2 is R^3 or L_2R^3 ;

R^3 is selected from an unsubstituted C_3 - C_8 cycloalkyl, a cyclobutanone, a cyclopentanone and a substituted C_3 - C_8 cycloalkyl,

wherein the substituted C_3 - C_8 cycloalkyl of R^3 is substituted with 1-4

substituents independently selected from C_1 - C_6 alkyl, halo, C_1 - C_6 haloalkyl, $-OR^4$, -CN, $-C(=O)OR^4$, $-C(=O)R^4$, $-C(=O)R^7$, $-C(=O)OR^5$, $-(CR^9_2)_nOR^4$, $-O(CR^9_2)_nOR^4$, $-C(=O)O(CR^9_2)_nOR^4$, $-N(R^4)_2$, $=N-OR^4$, $=N-O-(CR^9_2)_nR^5$, $-C(=O)NR^4_2$, $-NR^4C(=O)OR^4$, $-NR^4C(=O)(CR^9_2)_nOR^4$, $-NR^4(CR^9_2)_nOR^4$, $-NR^4S(=O)_2R^4$, $-N(C(=O)OR^4)_2$, $=CH_2$, $=CH(CR^9_2)_nOR^4$, R^8 , $-(CR^9_2)_nR^8$, deuterated C_1 - C_6 alkoxy, $-S(=O)_2R^4$, $-S(=O)_2R^7$, $-S(=O)_2R^8$, $-S(=O)_2N(R^4)_2$, $-S(=O)_2NHC(=O)OR^4$, $-S(=O)_2(CR^9_2)_nC(=O)OR^4$, $-S(=O)_2(CR^9_2)_nOR^4$, a spiro attached dioxolane, a spiro attached dioxolane which is substituted with C_1 - C_6 alkyl, a spiro attached dioxane, a spiro attached tetrahydrofuranly, a spiro attached oxetane, a spiro attached

cyclobutanone, a spiro attached cyclobutanol, a C₁ alkyl bridge, an unsubstituted 5-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O and S, a 5-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O and S substituted with 1-3 substituents independently selected from C₁-C₆alkyl, halo, C₁-C₆haloalkyl, C₁-C₆haloalkoxy, -OR⁴ and R⁸;

5 each R⁴ is independently selected from H and C₁-C₆alkyl;

R⁵ is an unsubstituted C₃-C₈cycloalkyl, an unsubstituted 5-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N or O or a C₃-C₈cycloalkyl substituted with 1-3 substituents independently selected from C₁-C₆alkyl;

10 each R⁶ is independently selected from -NHC(O)OR⁴, -OR⁴ and -(CR⁹)_nOR⁴;

each R⁷ is independently selected from C₁-C₆haloalkyl;

R⁸ is selected from an unsubstituted phenyl, unsubstituted 5-6 membered heteroaryl with 1-3 heteroatoms independently selected from N, O or S, an unsubstituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, an unsubstituted 4-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O or S, an unsubstituted C₃-C₈cycloalkyl, a substituted 5-6 membered heteroaryl with 1-3 heteroatoms independently selected from N, O or S, a substituted phenyl, a substituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, a substituted 4-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O or S, a substituted C₃-C₈cycloalkyl, a oxazolidin-2-one, pyrrolidinone and a pyrrolidin-2-one,

15

20 wherein the substituted phenyl, the substituted 5-6 membered heteroaryl with 1-3 heteroatoms independently selected from N, O or S, the substituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, substituted C₃-C₈cycloalkyl and substituted 4-6 membered heterocycloalkyl of R⁸ are substituted with 1-3 substituents independently selected from C₁-C₆alkyl, -(C(R⁹)₂)_nOR⁴, -(C(R⁹)₂)_nR⁵, -(C(R⁹)₂)_nC(O)OR⁴, -C(O)OR⁴ and -S(O)₂R⁴;

25 each R⁹ is independently selected from H and C₁-C₆alkyl;

R¹⁰ is selected from an unsubstituted phenyl, unsubstituted 5-6 membered heteroaryl with 1-2 heteroatoms independently selected from N, O or S, an unsubstituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, an unsubstituted 4-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O or S, an unsubstituted C₃-C₈cycloalkyl, a substituted 5-6 membered heteroaryl with 1-2 heteroatoms independently

30

35


selected from N, O or S, a substituted phenyl, a substituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, a substituted 4-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O or S, a substituted C₃-C₈cycloalkyl, a oxazolidin-2-one, pyrrolidinone and a pyrrolidin-2-one,

wherein the substituted phenyl, the substituted 5-6 membered heteroaryl with 1-2 heteroatoms independently selected from N, O or S, the substituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, substituted C₃-C₈cycloalkyl and substituted 4-6 membered heterocycloalkyl of R¹⁰ are substituted with 1-3 substituents independently selected from C₁-C₆alkyl, -C(R⁹)₂nOR⁴, -C(R⁹)₂nR⁵, -C(R⁹)₂nC(O)OR⁴ and -S(O)₂R⁴;


t is 1, 2 or 3, and

each n is independently selected from 1, 2, 3 and 4.


2. The compound of claim 1, wherein the compound is a compound of Formula (Ia),
Formula (IIa), Formula (Ib) or Formula (IIb):




Formula (Ia)



Formula (IIa)



Formula (Ib)



Formula (IIb)

wherein:

m is 1 and R²⁰ is selected from H, halo, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆haloalkoxy, deuterium, deuterated C₁-C₆alkyl, -CN, -(CR⁹)₂nOR⁴, -C(O)R⁴, -(CR⁹)₂nC(=O)OR⁴, R¹⁰, -(CR⁹)₂nR¹⁰, -((CR⁹)₂nO)_tR⁴, -(CR⁹)₂nO(CR⁹)₂nR⁷, -(CR⁹)₂nC(=O)R⁴, -C(=O)N(R⁴)₂, -OR⁴ and -(CR⁹)₂nCN;

or m is 4 and R²⁰ is deuterium;

R¹ is selected from C₁-C₆alkyl and halo;

each R¹¹ is independently selected from H, halo, and C₁-C₆alkyl;

L_2 is $-(CR^9_2)_n-$, $-CHR^6-$, $-(CR^9_2)_nO-$, $-NH-$, $-(CR^9_2)_nC(=O)-$, $-C(=O)O(CR^9_2)_n-$,
 $-(CR^9_2)_nOC(=O)NR^4-$, $-(CR^9_2)_nNR^4C(=O)(CR^9_2)_n-$, $-(CR^9_2)_nNR^4C(=O)-$ or
 $-(CR^9_2)_nNR^4C(=O)O-$;

R^2 is R^3 or L_2R^3 ;

5 R^3 is selected from an unsubstituted C_3 - C_8 cycloalkyl, a cyclobutanone, a cyclopentanone and a substituted C_3 - C_8 cycloalkyl,

wherein the substituted C_3 - C_8 cycloalkyl of R^3 is substituted with 1-4

substituents independently selected from C_1 - C_6 alkyl, halo, C_1 -
 C_6 haloalkyl, $-OR^4$, $-CN$, $-C(=O)OR^4$, $-C(=O)R^4$, $-C(=O)R^7$, $-C(=O)OR^5$,
10 $-(CR^9_2)_nOR^4$, $-O(CR^9_2)_nOR^4$, $-C(=O)O(CR^9_2)_nOR^4$, $-N(R^4)_2$, $=N-OR^4$,
 $=N-O-(CR^9_2)_nR^5$, $-C(=O)NR^4_2$, $-NR^4C(=O)OR^4$,
 $-NR^4C(=O)(CR^9_2)_nOR^4$, $-NR^4(CR^9_2)_nOR^4$, $-NR^4S(=O)_2R^4$,
 $-N(C(=O)OR^4)_2$, $=CH_2$, $=CH(CR^9_2)_nOR^4$, R^8 , $-(CR^9_2)_nR^8$, deuterated C_1 -
 C_6 alkoxy, $-S(=O)_2R^4$, $-S(=O)_2R^7$, $-S(=O)_2R^8$, $-S(=O)_2N(R^4)_2$,
15 $-S(=O)_2NHC(=O)OR^4$, $-S(=O)_2(CR^9_2)_nC(=O)OR^4$, $-S(=O)_2(CR^9_2)_nOR^4$, a
spiro attached dioxolane, a spiro attached dioxolane which is
substituted with C_1 - C_6 alkyl, a spiro attached dioxane, a spiro attached
tetrahydrofuranly, a spiro attached oxetane, a spiro attached
cyclobutanone, a spiro attached cyclobutanol, a C_1 alkyl bridge, an
20 unsubstituted 5-6 membered heterocycloalkyl with 1-2 heteroatoms
independently selected from N, O and S, a 5-6 membered
heterocycloalkyl with 1-2 heteroatoms independently selected from N,
O and S substituted with 1-3 substituents independently selected from
 C_1 - C_6 alkyl, halo, C_1 - C_6 haloalkyl, C_1 - C_6 haloalkoxy, $-OR^4$ and R^8 ;

25 each R^4 is independently selected from H and C_1 - C_6 alkyl;

R^5 is an unsubstituted C_3 - C_8 cycloalkyl, an unsubstituted 5-6 membered
heterocycloalkyl with 1-2 heteroatoms independently selected from N or O or a
 C_3 - C_8 cycloalkyl substituted with 1-3 substituents independently selected from
 C_1 - C_6 alkyl;

30 each R^6 is independently selected from $-NHC(=O)OR^4$, $-OR^4$ and $-(CR^9_2)_nOR^4$;

each R^7 is independently selected from C_1 - C_6 haloalkyl;

R^8 is selected from an unsubstituted phenyl, unsubstituted 5-6 membered
heteroaryl with 1-3 heteroatoms independently selected from N, O or S, an
unsubstituted 5 membered heteroaryl with 1-4 heteroatoms selected from N,
35 an unsubstituted 4-6 membered heterocycloalkyl with 1-2 heteroatoms
independently selected from N, O or S, an unsubstituted C_3 - C_8 cycloalkyl, a
substituted 5-6 membered heteroaryl with 1-3 heteroatoms independently

selected from N, O or S, a substituted phenyl, a substituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, a substituted 4-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O or S, a substituted C₃-C₆cycloalkyl, a oxazolidin-2-one, pyrrolidinone and a pyrrolidin-2-one,

wherein the substituted phenyl, the substituted 5-6 membered heteroaryl with 1-3 heteroatoms independently selected from N, O or S, the substituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, substituted C₃-C₆cycloalkyl and substituted 4-6 membered heterocycloalkyl of R⁸ are substituted with 1-3 substituents independently selected from C₁-C₆alkyl, -(C(R⁹)₂)_nOR⁴, -(C(R⁹)₂)_nR⁵, -(C(R⁹)₂)_nC(O)OR⁴, -C(O)OR⁴ and -S(O)₂R⁴;

each R⁹ is independently selected from H and C₁-C₆alkyl;

R¹⁰ is selected from an unsubstituted phenyl, unsubstituted 5-6 membered heteroaryl with 1-2 heteroatoms independently selected from N, O or S, an unsubstituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, an unsubstituted 4-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O or S, an unsubstituted C₃-C₆cycloalkyl, a substituted 5-6 membered heteroaryl with 1-2 heteroatoms independently selected from N, O or S, a substituted phenyl, a substituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, a substituted 4-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N, O or S, a substituted C₃-C₆cycloalkyl, a oxazolidin-2-one, pyrrolidinone and a pyrrolidin-2-one,

wherein the substituted phenyl, the substituted 5-6 membered heteroaryl with 1-2 heteroatoms independently selected from N, O or S, the substituted 5 membered heteroaryl with 1-4 heteroatoms selected from N, substituted C₃-C₆cycloalkyl and substituted 4-6 membered heterocycloalkyl of R¹⁰ are substituted with 1-3 substituents independently selected from C₁-C₆alkyl, -(C(R⁹)₂)_nOR⁴, -(C(R⁹)₂)_nR⁵, -(C(R⁹)₂)_nC(O)OR⁴ and -S(O)₂R⁴;

t is 1, 2 or 3, and

each n is independently selected from 1, 2, 3 and 4.

3. The compound of claim 1 or claim 2, wherein R¹ is selected from -CH₃ and F.
4. The compound of any one of claims 1 to 3, wherein R¹ is -CH₃.
5. The compound of any one of claims 1 to 4, wherein each R¹¹ is independently selected from H, F and -CH₃.
6. The compound of any one of claims 1 to 5, wherein each R¹¹ is H.

7. The compound of any one of claims 1 to 6, wherein R^3 is selected from an unsubstituted C_3 - C_8 cycloalkyl, a cyclobutanone, a cyclopentanone and a substituted C_3 - C_8 cycloalkyl, wherein the substituted C_3 - C_8 cycloalkyl of R^3 is substituted with 1-4 substituents independently selected from C_1 - C_6 alkyl, halo, C_1 - C_6 haloalkyl, $-OR^4$, $-(CR^9)_nOR^4$, $-O(CR^9)_nOR^4$, $-N(R^4)_2$, $=N-OR^4$, $=N-O-(CR^9)_nR^5$, $-NR^4C(=O)OR^4$, $-NR^4C(=O)(CR^9)_nOR^4$, $-NR^4(CR^9)_nOR^4$, $-NR^4S(=O)_2R^4$, $-N(C(=O)OR^4)_2$, $=CH_2$, $=CH(CR^9)_nOR^4$, R^8 , deuterated C_1 - C_6 alkoxy, a spiro attached dioxolane, a spiro attached dioxolane which is substituted with C_1 - C_6 alkyl, a spiro attached dioxane, a spiro attached tetrahydrofuranly, a spiro attached cyclobutanone, a spiro attached cyclobutanol, an unsubstituted 5-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N and O and a 5-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N and O substituted with 1-3 substituents independently selected from C_1 - C_6 alkyl.
8. The compound of any one of claims 1 to 7, wherein each R^4 is independently selected from H, methyl, ethyl, propyl, butyl, i-propyl and t-butyl.
9. The compound of any one of claims 1 to 8, wherein R^5 is independently selected from cyclopropyl or morpholinyl.
10. The compound of any one of claims 1 to 9, wherein each R^7 is independently selected from CH_2F , $-CHF_2$, $-CH_2CHF_2$, $-CH_2CF_3$ and $-CF_3$.
11. The compound of any one of claims 1 to 10, wherein each R^9 is independently selected from H, methyl and ethyl.
12. The compound of any one of claims 1 to 11, wherein R^8 is selected from an unsubstituted C_3 - C_8 cycloalkyl and an unsubstituted 5 membered heteroaryl with 1-4 heteroatoms selected from N.
13. The compound of any one of claims 1 to 12, wherein R^3 is selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, each of which is unsubstituted or each of which is substituted with 1-4 substituents independently selected from $-F$, $-CH_3$, $-CH_2CH_3$, $-CF_3$, $-OH$, $-OCH_3$, $-CH_2OCH_3$, $-NH_2$, $-N(CH_3)_2$, $-OCH_2CH_2OCH_3$, $=N-OCH_3$, $=N-OCH_2CH_3$, $=N-OCH(CH_3)_2$, $=N-OH$, $=N-O-CH_2R^5$, $=N-O-CH_2CH_2R^5$, $-NHC(=O)OC(CH_3)_3$, $-NHC(=O)OCH_3$, $-NHC(=O)CH_2OCH_3$, $-NHCH_2CH_2OCH_3$, $-NHCH_2CH_2OH$, $-NHS(=O)_2CH_3$, $-N(C(=O)OCH_3)_2$, $=CH_2$, $=CHCH_2CH_2OH$, $-OCD_3$, cyclopropyl, triazolyl, pyrazolyl, a spiro attached dioxolane, a spiro attached dioxolane which is substituted with a $-CH_3$, a spiro attached dioxane, a spiro

attached tetrahydrofuranly, a spiro attached cyclobutanone, a spiro attached cyclobutanol, piperidinyl and piperazinyl substituted with a $-\text{CH}_3$,

or R^3 is a cyclobutanone or a cyclopentanone.

14. The compound of any one of claims 1 to 13, wherein:

5 R^3 is cyclopropyl substituted with 1 or 2 F,

or

R^3 is cyclobutyl substituted with 2 F.

15. The compound of any one of claims 1 to 14, wherein m is 1 and R^{20} is selected from H, halo, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ haloalkoxy, deuterated $\text{C}_1\text{-C}_6$ alkyl, $-\text{CN}$,

10 $-(\text{CR}^9)_n\text{OR}^4$, $-(\text{CR}^9)_n\text{C}(=\text{O})\text{OR}^4$, R^{10} , $-(\text{CR}^9)_n\text{R}^{10}$, $-((\text{CR}^9)_n\text{O})_t\text{R}^4$, $-(\text{CR}^9)_n\text{O}(\text{CR}^9)_n\text{R}^7$, $-(\text{CR}^9)_n\text{C}(=\text{O})\text{R}^4$, and $-\text{C}(=\text{O})\text{N}(\text{R}^4)_2$.

16. The compound of any one of claims 1 to 15, wherein m is 1 and R^{20} is selected from H, $-\text{F}$, $-\text{CH}_3$, $-\text{CF}_3$, $-\text{CD}_3$, $-\text{CN}$, $-\text{OCHF}_2$, $-\text{C}(\text{CH}_3)\text{OH}$, $-\text{CH}_2\text{CH}_2\text{C}(=\text{O})\text{OC}(\text{CH}_3)_3$,

15 $-\text{CH}_2\text{OCH}_2\text{CH}_2\text{OH}$, $-\text{CH}_2\text{OCH}_2\text{CF}_3$, $-\text{C}(=\text{O})\text{NH}_2$, $-\text{CH}_2\text{CH}_2\text{C}(\text{CH}_3)_2\text{OH}$, $-\text{CH}_2\text{OCH}_2\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{OCH}_2\text{CH}_2\text{F}$, $-\text{CH}_2\text{CH}_2\text{C}(=\text{O})\text{CH}_3$, $-\text{CH}_2\text{OH}$ and $-\text{CH}_2\text{OCH}_3$.

17. The compound of any one of claims 1 to 16, wherein m is 1 and R^{20} is $-\text{CH}_3$.

18. The compound of any one of claims 1 to 16, wherein m is 1 and R^{20} is H.

19. The compound of any one of claims 1 to 18, wherein:

20 R^{10} is selected from morpholinyl, piperidinyl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazinyl, piperazin-1-yl, pyrazolyl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, triazolyl, 1H-1,2,3-triazol-4-yl, 4H-1,2,4-triazol-3-yl, 1H-1,2,4-triazol-5-yl, thiazolyl, thiazol-4-yl, thiazol-5-yl, imidazolyl, imidazol-1-yl, imidazol-2-yl, each of which is unsubstituted or each of which is substituted with 1-3 substituents independently selected from $\text{C}_1\text{-C}_6$ alkyl, $-(\text{CR}^9)_n\text{OR}^4$, $-(\text{C}(\text{R}^9)_2)_n\text{C}(\text{O})\text{OR}^4$, $-(\text{C}(\text{R}^9)_2)_n\text{R}^5$ and $-\text{S}(=\text{O})_2\text{R}^4$,

25 or R^{10} is selected from a oxazolidin-2-one and a pyrrolidin-2-one.

20. The compound of any one of claims 1 to 19, wherein:

30 R^{10} is selected from morpholinyl, piperidinyl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazinyl, piperazin-1-yl, pyrazolyl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, triazolyl, 1H-1,2,3-triazol-4-yl, 4H-1,2,4-triazol-3-yl, 1H-1,2,4-triazol-5-yl, thiazolyl, thiazol-4-yl, thiazol-5-yl, imidazolyl, imidazol-1-yl, imidazol-2-yl, each of which is unsubstituted or each of which is substituted with 1-3 substituents independently selected from $-\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{OH}$, $-\text{CH}_2\text{C}(\text{O})\text{OH}$, $-\text{CH}_2\text{CH}_2\text{OH}$, $-\text{CH}_2\text{C}(\text{CH}_3)_2\text{OH}$, $-\text{S}(\text{O})_2\text{CH}_3$ and $-\text{CH}_2\text{CH}_2\text{-R}_5$.

21. The compound of any one of claims 1 to 14, wherein m is 4 and R²⁰ is deuterium.
22. The compound of claim 1 selected from the group consisting of:
N-{5-[3-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-5-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
5 N-{2-methyl-5-[5-(3-oxocyclopentyl)-1,2,4-oxadiazol-3-yl]phenyl}imidazo[1,2-a]pyridine-3-carboxamide;
N-{5-[5-(3-hydroxy-3-methylcyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
N-{5-[5-[3-(hydroxyimino)cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
10 N-{5-[5-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
N-{5-[5-(3-hydroxy-3-methylcyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
15 N-{5-[5-[3-(methoxyimino)cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
N-{5-[5-[5,8-dioxaspiro[3.4]octan-2-yl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
N-(2-methyl-5-[5-[(6R)-6-methyl-5,8-dioxaspiro[3.4]octan-2-yl]-1,2,4-oxadiazol-3-yl]phenyl)imidazo[1,2-a]pyridine-3-carboxamide;
20 N-[5-(5-[5,9-dioxaspiro[3.5]nonan-2-yl]-1,2,4-oxadiazol-3-yl)-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
N-(2-methyl-5-[5-(3-oxocyclobutyl)-1,2,4-oxadiazol-3-yl]phenyl)imidazo[1,2-a]pyridine-3-carboxamide;
25 N-(2-methyl-5-[5-[(6S)-6-methyl-5,8-dioxaspiro[3.4]octan-2-yl]-1,2,4-oxadiazol-3-yl]phenyl)imidazo[1,2-a]pyridine-3-carboxamide;
N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
N-[5-[5-[3-(ethoxyimino)cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
30 N-[5-[5-[3-[(cyclopropylmethoxy)imino]cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
N-[2-methyl-5-(5-[3-[(propan-2-yloxy)imino]cyclobutyl]-1,2,4-oxadiazol-3-yl]phenyl)imidazo[1,2-a]pyridine-3-carboxamide;
35 N-[5-[5-(3-aminocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;

- N-(5-{5-[3-(2-methoxyethoxy)cyclobutyl]-1,2,4-oxadiazol-3-yl}-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3-methoxycyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 5 N-(5-{5-[1-(methoxymethyl)cyclopropyl]-1,2,4-oxadiazol-3-yl}-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- tert-butyl N-{1-[3-(3-{imidazo[1,2-a]pyridine-3-amido}-4-methylphenyl)-1,2,4-oxadiazol-5-yl]cyclopropyl}carbamate;
- N-{5-[5-(1-methanesulfonamidocyclopropyl)-1,2,4-oxadiazol-3-yl]-2-
- 10 methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- methyl N-{1-[3-(3-{imidazo[1,2-a]pyridine-3-amido}-4-methylphenyl)-1,2,4-oxadiazol-5-yl]cyclopropyl}-N-(methoxycarbonyl)carbamate;
- methyl N-{1-[3-(3-{imidazo[1,2-a]pyridine-3-amido}-4-methylphenyl)-1,2,4-oxadiazol-5-yl]cyclopropyl}carbamate;
- 15 N-(5-{5-[3-hydroxy-3-(trifluoromethyl)cyclobutyl]-1,2,4-oxadiazol-3-yl}-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- 1-methylcyclopropyl N-[[3-(3-{imidazo[1,2-a]pyridine-3-amido}-4-methylphenyl)-1,2,4-oxadiazol-5-yl]methyl]carbamate;
- methyl N-{1-[3-(3-{imidazo[1,2-a]pyridine-3-amido}-4-methylphenyl)-1,2,4-oxadiazol-5-yl]cyclobutyl}carbamate;
- 20 N-{5-[5-(1-methanesulfonamidocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-(5-{5-[1-(dimethylamino)cyclopropyl]-1,2,4-oxadiazol-3-yl}-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- 25 N-{2-methyl-5-[5-(3-methylidenecyclobutyl)-1,2,4-oxadiazol-3-yl]phenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3-cyclopropyl-3-hydroxycyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-(5-{5-[3-(3-hydroxypropylidene)cyclobutyl]-1,2,4-oxadiazol-3-yl}-2-
- 30 methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-[2-methyl-5-(5-{5-oxaspiro[3.4]octan-2-yl}-1,2,4-oxadiazol-3-yl)phenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-[5-(5-[[3,3-difluorocyclobutyl]amino]methyl)-1,2,4-oxadiazol-3-yl]-2-
- methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- 35 N-(2-methyl-5-{5-[(2,2,3,3-tetrafluorocyclobutoxy)methyl]-1,2,4-oxadiazol-3-yl}phenyl)imidazo[1,2-a]pyridine-3-carboxamide;

- N-{5-[5-(3-fluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(hydroxymethyl)imidazo[1,2-a]pyridine-3-carboxamide;
- 5 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[(2-hydroxyethoxy)methyl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(methoxymethyl)imidazo[1,2-a]pyridine-3-carboxamide;
- 10 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- 15 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(1-methyl-1H-pyrazol-3-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-(2-methyl-5-{5-[3-(1H-pyrazol-1-yl)cyclobutyl]-1,2,4-oxadiazol-3-yl}phenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- 20 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(1,3-thiazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-fluorophenyl}-6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- 25 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-fluorophenyl}-6-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-7-(1-methanesulfonylpiperidin-4-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[1-(2-(morpholin-4-yl)ethyl)-1H-pyrazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide;
- 30 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-fluorophenyl}-6-[1-(2-(morpholin-4-yl)ethyl)-1H-pyrazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[(2,2,2-trifluoroethoxy)methyl]imidazo[1,2-a]pyridine-3-carboxamide;
- 35 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(3-oxobutyl)imidazo[1,2-a]pyridine-3-carboxamide;

- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(3-hydroxy-3-methylbutyl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-[2-(1-hydroxycyclopropyl)ethyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 5 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[2-(morpholin-4-yl)ethyl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(cyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 10 N-{5-[5-(3,3-dimethylcyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-7-(morpholin-4-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- 6-cyano-N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 15 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-fluorophenyl}-6-(5-methyl-4H-1,2,4-triazol-3-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- 3-N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3,6-dicarboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[2-(4-methylpiperazin-1-yl)ethyl]imidazo[1,2-a]pyridine-3-carboxamide;
- 20 N-{5-[5-(2,2-difluorocyclopropyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-7-(1H-1,2,3-triazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- 25 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-7-[1-(2-hydroxyethyl)-1H-1,2,3-triazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2,4-dimethylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-7-(2-oxo-1,3-oxazolidin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- 30 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-7-methylimidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-methylimidazo[1,2-a]pyridine-3-carboxamide;
- 35 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-fluoroimidazo[1,2-a]pyridine-3-carboxamide;

- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-7-fluoroimidazo[1,2-a]pyridine-3-carboxamide;
- 7-cyano-N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 5 N-[5-(5-cyclopentyl-1,2,4-oxadiazol-3-yl)-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-[2-methyl-5-(5-{6-oxospiro[3.3]heptan-2-yl}-1,2,4-oxadiazol-3-yl)phenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-7-(2-oxopyrrolidin-1-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- 10 N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-6-[(2,2-difluoroethoxy)methyl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-[5-[5-(3-ethylcyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- 15 N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-6-(5-methyl-4H-1,2,4-triazol-3-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-7-methylimidazo[1,2-a]pyridine-3-carboxamide;
- N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-6-(morpholin-4-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- 20 N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-6-(1H-imidazol-1-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-6-[(2-fluoroethoxy)methyl]imidazo[1,2-a]pyridine-3-carboxamide;
- 25 N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-6-[3-(methoxymethyl)-1H-1,2,4-triazol-5-yl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-[5-[5-(2,2-difluorocyclopropyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-6-[(2,2,2-trifluoroethoxy)methyl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-[5-(5-cyclobutyl-1,2,4-oxadiazol-3-yl)-2-methylphenyl]-6-[(2,2,2-trifluoroethoxy)methyl]imidazo[1,2-a]pyridine-3-carboxamide;
- 30 N-(5-{5-[(1R)-2,2-difluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-(5-{5-[(1S)-2,2-difluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- 35 N-(5-{5-[3-hydroxy-3-(trifluoromethyl)cyclobutyl]-1,2,4-oxadiazol-3-yl}-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine-3-carboxamide;

- 6-fluoro-N-(5-[5-[3-hydroxy-3-(trifluoromethyl)cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
 N-(5-[5-[(1R,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- 5 N-(5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl)-5,6,7,8-tetradeuteroimidazo[1,2-a]pyridine-3-carboxamide;
 N-[5-[(3,3-difluorocyclobutyl)carbamoyl]-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- 10 7-fluoro-N-(5-[5-[3-hydroxy-3-(trifluoromethyl)cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
 N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-6-(4-methyl-1H-imidazol-1-yl)imidazo[1,2-a]pyridine-3-carboxamide;
 N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]imidazo[1,2-a]pyridine-3-carboxamide;
- 15 N-(5-[5-[3-methoxy-3-(trifluoromethyl)cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
 6-fluoro-N-(5-[5-[1-(methoxymethyl)cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
 N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-6-[1-(2-methoxyethyl)-5-methyl-1H-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridine-3-carboxamide;
- 20 N-[5-[5-[6-hydroxyspiro[3.3]heptan-2-yl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
 N-(5-[5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- 25 7-methyl-N-(2-methyl-5-[5-[(2,2,3,3-tetrafluorocyclobutoxy)methyl]-1,2,4-oxadiazol-3-yl]phenyl)imidazo[1,2-a]pyridine-3-carboxamide;
 6-methyl-N-(2-methyl-5-[5-[(2,2,3,3-tetrafluorocyclobutoxy)methyl]-1,2,4-oxadiazol-3-yl]phenyl)imidazo[1,2-a]pyridine-3-carboxamide;
 N-[5-[5-cyclopropyl-1,2,4-oxadiazol-3-yl]-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- 30 N-[5-[5-(cyclopropylmethyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
 N-(5-[5-[(1R,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine-3-carboxamide;
- 35 N-(5-[5-[(1S,2R)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine-3-carboxamide;

- N-(5-[5-[(1R)-2,2-difluorocyclopropyl]-1,2,4-oxadiazol-3-yl]-2,4-dimethylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-(5-[5-[(1S)-2,2-difluorocyclopropyl]-1,2,4-oxadiazol-3-yl]-2,4-dimethylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- 5 N-(5-[5-[(1R,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-[5-[5-(3-fluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-7-methylimidazo[1,2-a]pyridine-3-carboxamide;
- 10 N-[5-[5-(3-fluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-6-methylimidazo[1,2-a]pyridine-3-carboxamide;
- N-(5-[5-[(1S,2R)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- methyl N-[3,3-difluoro-1-[3-(3-{imidazo[1,2-a]pyridine-3-amido}-4-methylphenyl)-1,2,4-oxadiazol-5-yl]cyclobutyl]carbamate;
- 15 methyl N-[3,3-difluoro-1-[3-(4-methyl-3-{7-methylimidazo[1,2-a]pyridine-3-amido}phenyl)-1,2,4-oxadiazol-5-yl]cyclobutyl]carbamate,
- N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-6-[(2-fluoroethoxy)methyl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-[5-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- 20 N-[5-[5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazol-2-yl]-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-[5-[5-(3-hydroxy-3-methylcyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- 25 N-(5-[5-[(3Z)-3-(methoxyimino)cyclopentyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-(5-[5-[(3Z)-3-(hydroxyimino)cyclopentyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- 30 N-(2-methyl-5-[5-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-3-yl]phenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-[5-[5-(3-hydroxy-3-methylcyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-(2-methyl-5-[5-(3-oxocyclobutyl)-1,2,4-oxadiazol-3-yl]phenyl)imidazo[1,2-a]pyridine-3-carboxamide;

- N-{5-[5-(3-hydroxycyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-(2-methyl-5-{5-[3-(piperidin-1-yl)cyclobutyl]-1,2,4-oxadiazol-3-yl}phenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- 5 N-(2-methyl-5-{5-[3-(morpholin-4-yl)cyclobutyl]-1,2,4-oxadiazol-3-yl}phenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-(2-methyl-5-{5-[3-(4-methylpiperazin-1-yl)cyclobutyl]-1,2,4-oxadiazol-3-yl}phenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- 10 N-{2-methyl-5-[5-(3-[[2-(morpholin-4-yl)ethoxy]imino]cyclobutyl)-1,2,4-oxadiazol-3-yl]phenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- tert-butyl N-{3-[3-(3-{imidazo[1,2-a]pyridine-3-amido}-4-methylphenyl)-1,2,4-oxadiazol-5-yl]cyclobutyl}carbamate;
- N-{5-[5-(3-aminocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 15 N-{5-[5-(3-methanesulfonamidocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 1-methylcyclopropyl N-{2-[3-(3-{imidazo[1,2-a]pyridine-3-amido}-4-methylphenyl)-1,2,4-oxadiazol-5-yl]ethyl}carbamate;
- N-{5-[5-(1-aminocyclopropyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 20 N-(5-[5-[1-(2-methoxyacetamido)cyclopropyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-[3-[(2-methoxyethyl)amino]cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 25 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-fluorophenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-[3-methoxy-3-(trifluoromethyl)cyclobutyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-N-methylimidazo[1,2-a]pyridine-3-carboxamide;
- tert-butyl N-{1-[3-(3-{imidazo[1,2-a]pyridine-3-amido}-4-methylphenyl)-1,2,4-oxadiazol-5-yl]cyclobutyl}carbamate;
- 30 N-{5-[5-(1-aminocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;

- N-{2-fluoro-5-[5-(3-methylidenecyclobutyl)-1,2,4-oxadiazol-3-yl]phenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-(5-[5-[1-(hydroxymethyl)cyclopropyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- 5 N-[5-[5-[(2,2-difluorocyclopropyl)formamido]methyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- 1-methylcyclopropyl N-[(3-[4-methyl-3-[7-(trifluoromethyl)imidazo[1,2-a]pyridine-3-amido]phenyl]-1,2,4-oxadiazol-5-yl)methyl]carbamate;
- 10 methyl N-{3-[3-(3-[imidazo[1,2-a]pyridine-3-amido]-4-methylphenyl)-1,2,4-oxadiazol-5-yl]cyclobutyl}carbamate;
- N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-6-[(4-methylpiperazin-1-yl)methyl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-6-[(4-(2-hydroxyethyl)piperazin-1-yl)methyl]imidazo[1,2-a]pyridine-3-carboxamide;
- 15 N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-6-[(2-methoxyethoxy)methyl]imidazo[1,2-a]pyridine-3-carboxamide;
- 2-[4-[3-[(5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl)carbamoyl]imidazo[1,2-a]pyridin-6-yl]-1H-pyrazol-1-yl]acetic acid;
- N-[5-[5-(1-hydroxycyclopropyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- 20 N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-7-(difluoromethoxy)imidazo[1,2-a]pyridine-3-carboxamide;
- N-(2-methyl-5-[5-[3-(1H-1,2,4-triazol-1-yl)cyclobutyl]-1,2,4-oxadiazol-3-yl]phenyl)imidazo[1,2-a]pyridine-3-carboxamide;
- 25 6-fluoro-N-[5-[5-(3-hydroxycyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-[5-[5-(cyclobutyl)-1,2,4-oxadiazol-3-yl]-2-fluorophenyl]imidazo[1,2-a]pyridine-3-carboxamide;
- N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-6-(2-hydroxy-2-methylpropyl)imidazo[1,2-a]pyridine-3-carboxamide;
- 30 N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl]-6-[(2-oxo-1,3-oxazolidin-3-yl)methyl]imidazo[1,2-a]pyridine-3-carboxamide;

- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-7-(2-hydroxy-2-methylpropyl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-dimethylcyclobutyl)-1,2,4-oxadiazol-3-yl]-2-fluorophenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 5 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-fluorophenyl}-6-(5-methyl-4H-1,2,4-triazol-3-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- 6-fluoro-N-{5-[5-(3-hydroxy-3-methylcyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 10 N-{5-[5-(2-hydroxycyclopropyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- N-{3-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2,6-dimethylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 7-cyano-N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 15 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(1-hydroxyethyl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(5-methyl-1H-imidazol-1-yl)imidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[(2-methoxyethoxy)methyl]imidazo[1,2-a]pyridine-3-carboxamide;
- 20 N-{5-[5-[(1S)-2,2-difluorocyclopropyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-7-methylimidazo[1,2-a]pyridine-3-carboxamide;
- N-{5-[5-(1-fluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- 25 N-{5-[5-(1-hydroxycyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
- tert-butyl 3-[3-({5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}carbamoyl)imidazo[1,2-a]pyridin-6-yl]propanoate;
- N-{5-[5-(1-carbamoylcyclopropyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-fluoroimidazo[1,2-a]pyridine-3-carboxamide and
- 30 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-7-(piperidin-4-yl)imidazo[1,2-a]pyridine-3-carboxamide.

23. The compound of claim 1 selected from the group consisting of:
 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}imidazo[1,2-a]pyridine-3-carboxamide;
 N-(5-[5-[(1R)-2,2-difluorocyclopropyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
 5 N-(5-[5-[(1S)-2,2-difluorocyclopropyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide;
 N-(5-[5-[(1S,2R)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide, and
 10 N-(5-[5-[(1R,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl]-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide.
24. A pharmaceutical composition comprising a therapeutically effective amount a compound of any one of claims 1 to 23 and a pharmaceutically acceptable carrier.
25. Use of a compound of any one of claims 1 to 23 in the manufacture of a medicament for
 15 treating a disease or disorder in a patient where modulation of a kinase is implicated, wherein the kinase is selected from c-kit, PDGFR α and PDGFR β , and wherein the disease is selected from the group consisting of a mast-cell associated disease, a respiratory disease, an inflammatory disorder, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), an autoimmune disorder, a metabolic disease, a
 20 fibrosis disease, a dermatological disease, pulmonary arterial hypertension (PAH) and primary pulmonary hypertension (PPH).
26. The use of claim 25, wherein the disease is selected from the group consisting of asthma, allergic rhinitis, pulmonary arterial hypertension (PAH), pulmonary fibrosis, hepatic fibrosis, cardiac fibrosis, scleroderma, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), urticaria, dermatosis, atopic dermatitis, allergic contact dermatitis, rheumatoid arthritis, multiple sclerosis, melanoma, a gastrointestinal stromal tumor, a mast cell tumor, mastocytosis, anaphylactic syndrome, type I diabetes or type II diabetes.